• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何使用异常不自主运动量表对患者进行检查。

How to examine patients using the Abnormal Involuntary Movement Scale.

作者信息

Munetz M R, Benjamin S

机构信息

Department of Psychiatry, University of Massachusetts Medical Center, Worcester 01655.

出版信息

Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. doi: 10.1176/ps.39.11.1172.

DOI:10.1176/ps.39.11.1172
PMID:2906320
Abstract

The Abnormal Involuntary Movement Scale (AIMS) examination has been widely recommended for periodic screening for tardive dyskinesia and follow-up of patients diagnosed with the disorder. However, few guidelines exist about how to use the examination in clinical practice. The authors discuss for whom, when, and how the AIMS examination can be used in a multidisciplinary setting; amplify the original instructions for the examination; and propose conventions to clarify scoring. Noting that the AIMS examination is not specific for tardive dyskinesia, they discuss a clinical approach to the patient who is found to have abnormal movements. The AIMS examination is best conducted within the context of an ongoing treatment program, the authors say, and should be part of the informed consent process necessary with patients treated with neuroleptic drugs.

摘要

异常不自主运动量表(AIMS)检查已被广泛推荐用于迟发性运动障碍的定期筛查以及对被诊断患有该疾病患者的随访。然而,关于如何在临床实践中使用该检查的指南却很少。作者们讨论了在多学科环境中AIMS检查适用于哪些人、何时使用以及如何使用;扩充了该检查的原始说明;并提出了明确评分的惯例。他们指出AIMS检查并非迟发性运动障碍所特有,还讨论了针对被发现有异常运动患者的临床处理方法。作者们表示,AIMS检查最好在正在进行的治疗方案背景下进行,并且应该是使用抗精神病药物治疗患者所需的知情同意过程的一部分。

相似文献

1
How to examine patients using the Abnormal Involuntary Movement Scale.如何使用异常不自主运动量表对患者进行检查。
Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. doi: 10.1176/ps.39.11.1172.
2
CMHC practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs.与迟发性运动障碍筛查及抗精神病药物知情同意相关的社区精神卫生中心实践。
Hosp Community Psychiatry. 1994 Apr;45(4):343-6. doi: 10.1176/ps.45.4.343.
3
Screening for tardive dyskinesia.
J Clin Psychiatry. 1986 Feb;47(2):75-7.
4
Who should perform the AIMS examination?
Hosp Community Psychiatry. 1990 Aug;41(8):912-5. doi: 10.1176/ps.41.8.912.
5
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.接受抗精神病药物治疗的患者迟发性运动障碍病程的预测因素。
Biol Psychiatry. 1992 Oct 1;32(7):580-94. doi: 10.1016/0006-3223(92)90071-7.
6
Not all that moves is tardive dyskinesia.并非所有的运动都是迟发性运动障碍。
Am J Psychiatry. 1991 May;148(5):661-6. doi: 10.1176/ajp.148.5.661.
7
Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.极重度智力障碍者的系统性运动障碍检查:合作与评估
Am J Ment Defic. 1987 Sep;92(2):155-60.
8
Tardive tremor.迟发性震颤
Mov Disord. 1992;7(1):53-7. doi: 10.1002/mds.870070110.
9
An unusual movement disorder associated with neuroleptic treatment: tardive dyskinesia?一种与抗精神病药物治疗相关的不寻常运动障碍:迟发性运动障碍?
J Nerv Ment Dis. 1980 Jul;168(7):442-4. doi: 10.1097/00005053-198007000-00010.
10
Neuroleptic-induced respiratory dyskinesia.抗精神病药所致呼吸运动障碍
J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):223-9. doi: 10.1176/jnp.7.2.223.

引用本文的文献

1
Extrapyramidal side effects with nonantipsychotic medications.非抗精神病药物的锥体外系副作用。
Ment Health Clin. 2024 Aug 2;14(4):233-235. doi: 10.9740/mhc.2024.08.233. eCollection 2024 Aug.
2
The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review.抗精神病药物对精神分裂症认知功能的影响——当前叙述性综述
Brain Sci. 2024 Apr 3;14(4):359. doi: 10.3390/brainsci14040359.
3
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review.
通过临床医生调查和病历审查,探索VMAT2抑制剂治疗的迟发性运动障碍患者的现实世界症状影响和幸福感领域的改善情况。
Ment Health Clin. 2023 Oct 2;13(5):225-232. doi: 10.9740/mhc.2023.10.225. eCollection 2023 Oct.
4
Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients.全基因组关联研究确定了六个与精神分裂症患者对阿立哌唑药物不良反应相关的基因座。
Schizophrenia (Heidelb). 2023 Jul 25;9(1):44. doi: 10.1038/s41537-023-00369-6.
5
Medical and Surgical Treatment for Medication-Induced Tremor: Case Report and Systematic Review.药物性震颤的医学与外科治疗:病例报告及系统评价
Mov Disord Clin Pract. 2022 May 24;9(5):676-687. doi: 10.1002/mdc3.13463. eCollection 2022 Jul.
6
Psychotropic Medication Monitoring in a Human Services Organization for Children with Autism Spectrum Disorder: Description and Evaluation of Interdisciplinary Team Review.为患有自闭症谱系障碍的儿童提供服务的人类服务组织中的精神药物监测:跨学科团队审查的描述与评估
Behav Anal Pract. 2022 Mar 25;15(4):1337-1347. doi: 10.1007/s40617-022-00699-4. eCollection 2022 Dec.
7
Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.鲁拉西酮与安慰剂治疗初发及曾接受治疗的青少年精神分裂症急性加重期患者的短期疗效与安全性比较
Eur Psychiatry. 2022 Mar 24;65(1):1-35. doi: 10.1192/j.eurpsy.2022.11.
8
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency.AADC 缺乏症患者接受 eladocagene exuparvovec 治疗的长期疗效和安全性。
Mol Ther. 2022 Feb 2;30(2):509-518. doi: 10.1016/j.ymthe.2021.11.005. Epub 2021 Nov 8.
9
The Impact of THC and CBD in Schizophrenia: A Systematic Review.四氢大麻酚和大麻二酚对精神分裂症的影响:一项系统综述。
Front Psychiatry. 2021 Jul 23;12:694394. doi: 10.3389/fpsyt.2021.694394. eCollection 2021.
10
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia.精神分裂症患者个体化抗精神病药物治疗的药物基因组学研究方案。
BJPsych Open. 2021 Jun 29;7(4):e121. doi: 10.1192/bjo.2021.945.